Fondaparinux Sodium interactions

Conditions

Conditions in which Fondaparinux Sodium needs care, as documented in this source.

• Endocarditis, Bacterial

  Major

  The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.

  1 source

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):

• Hemorrhage

  Major

  The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages. Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications. Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis. In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.

  4 sources

  1. "Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals (2022):
  2. "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC (2020):
  3. "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb (2021):
  4. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc. (2021):

• Kidney Diseases

  Major

  The use of fondaparinux is contraindicated in patients with severe renal dysfunction (CrCl less than 30 mL/min). Fondaparinux increases the risk of bleeding in patients with renal dysfunction due to reduced clearance. This drug may cause prolonged anticoagulation in patients with CrCl 30 to 50 mL/min. Renal function should be assessed periodically during therapy, and fondaparinux should be discontinued immediately in patients who develop severe renal dysfunction while on treatment. After discontinuation of fondaparinux, its anticoagulant effects may persist for 2 to 4 days in patients with normal renal function and even longer in patients with renal dysfunction.

  1 source

  1. "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC (2020):

• Hepatic Insufficiency

  Moderate

  Patients with liver dysfunction may be vulnerable to bleeding during fondaparinux therapy; these patients should be observed closely for signs/symptoms of bleeding. No dose adjustment is recommended in patients with mild to moderate liver dysfunction. No pharmacokinetic data are available for patients with severe liver dysfunction; fondaparinux should be used cautiously in these patients.

  1 source

  1. "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC (2020):

• Thrombocytopenia

  Moderate

  Thrombocytopenia can occur with the administration of fondaparinux. Caution should be used when administered to patients with preexisting thrombocytopenia. Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.

  1 source

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):